[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"social-anxiety-disorder-sad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:social-anxiety-disorder-sad":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,74,103,131,157,185,219,240,264,283],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100609976","phase-3-study-to-evaluate-the-efficacy-and-safety-of-vqw-765-for-the-on-demand-treatment-of-social-anxiety-disorder-100609976",false,"NCT07221578","Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder","Inclusion Criteria:\n\n1. Ability and willingness to provide written informed consent.\n2. Male and female subjects aged 18-65 years, inclusive.\n3. Current diagnosis of social anxiety disorder.\n4. Liebowitz Social Anxiety Scale total score ≥60.\n5. Public Speaking Anxiety Scale total score ≥60.\n6. Hamilton Depression Rating Scale score ≤18.\n\nExclusion Criteria:\n\n1. Suicide attempts and\u002For suicidal ideation in the past 2 years or currently at risk of suicide in the opinion of the investigator.\n2. History of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders, obsessive-compulsive disorder, or autism spectrum disorder.\n3. Posttraumatic stress disorder or an eating disorder in the past 6 months.\n4. Substance or alcohol use disorder in the past 6 months or positive in drug\u002Falcohol screening.\n5. Psychotherapy in the past 6 months.\n6. Psychotropic medication in the past 2 months.\n7. Current or planned pregnancy or nursing during the trial period.\n8. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, or interference with study objectives.","ALL","18 Years","65 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.",[27],"Social Anxiety Disorder (SAD)",[29,30,31,32,33],"Social Anxiety Disorder","Social Phobia","SAD","Public Speaking Anxiety","Performance Anxiety","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-09-22",{"date":42,"type":21},"2027-04",{"name":44,"class":45},"Vanda Pharmaceuticals","INDUSTRY",31,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100644084","efficacy-of-attention-bias-modification-vs-placebo-for-social-anxiety-disorder-100644084","NCT07666776","Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety Disorder","Placebo Effects in Dot-Probe Attention Bias Modification (ABM) Among Adults With Social Anxiety Disorder.","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Primary diagnosis of generalized Social Anxiety Disorder based on clinical evaluation, the MINI International Neuropsychiatric Interview (MINI), and a Liebowitz Social Anxiety Scale (LSAS) score greater than 50\n* Normal or corrected-to-normal vision without color blindness\n* Sufficient Hebrew proficiency to complete clinical interviews, self-report questionnaires, and computerized cognitive tasks\n\nExclusion Criteria:\n\n* Previous participation in attention bias modification training using a dot-probe task\n* Previous participation in eye-tracking-based attention training\n* Current diagnosis of Post-Traumatic Stress Disorder\n* Current or past diagnosis of psychotic disorder or bipolar disorder\n* Neurological disorder (e.g., epilepsy or traumatic brain injury)\n* Severe suicidal ideation\n* Current substance or alcohol use disorder\n* Concurrent pharmacological or psychosocial treatment, unless medication has been stable for at least 45 days\n* Pregnancy\n* Uncorrected visual impairment or use of multifocal glasses",{"count":55,"type":21},90,[57],"NA","This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically related to changes in attentional processing or to nonspecific factors such as expectancy and placebo effects.",[27,60,61],"Attention Bias Modification Treatment (ABMT)","Placebo Effect",[63],"Social Anxiety; Placebo; Treatment; Attention Bias","2026-06-18",{"date":35,"type":38},{"date":67,"type":38},"2026-06-15",{"date":69,"type":21},"2027-06-30",{"name":71,"class":72},"Tel Aviv University","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100618000","online-radical-acceptance-intervention-for-social-anxiety-disorder-100618000","NCT07325929","Online Radical Acceptance Intervention for Social Anxiety Disorder","Online Radical Acceptance Intervention for Social Anxiety Disorder: a Randomized Controlled Trial","RA-SAD-001","Inclusion Criteria:\n\n* Aged 18-45\n* Score \\> 9 on Mini-SPIN\n* Positive responses in brief phone screening\n* Eligibility confirmed in Zoom interview using ADIS\n* Native Hebrew speakers\n* Having regular access to a computer.\n\nExclusion Criteria:\n\n* Changes in psychiatric medication in the past 3 months\n* Current or past diagnosis of bipolar disorder\n* Current or past diagnosis of schizophrenia\n* Current or past diagnosis of PTSD\n* Current or past diagnosis of substance use disorder\n* History of traumatic brain injury (TBI)\n* Previous experience with Dialectical Behavior Therapy (DBT)\n* Currently receiving psychotherapy specifically targeting social anxiety","45 Years",{"count":84,"type":21},100,[57],"The goal of this clinical trial is to learn if a self-guided online Radical Acceptance program helps reduce symptoms of Social Anxiety Disorder. The study will also compare this program to an online relaxation skills program.\n\nThe main questions are:\n\n* Does the Radical Acceptance program lower symptoms of Social Anxiety Disorder?\n* Is the Radical Acceptance program more helpful than relaxation skills?\n\nAdults with Social Anxiety Disorder will be randomly assigned to one of two online programs. They will complete a baseline learning session and six short home practice sessions over two weeks. Participants will answer surveys about their symptoms and complete brief computer tasks. Researchers will measure changes in social anxiety at several points during the study and again a few weeks and a few months later.",[27],[89,90,91,92,93],"social anxiety disorder","acceptance","emotion regulation","guided self-help","digital intervention","2026-04-30",{"date":96,"type":38},"2026-05-06",{"date":98,"type":38},"2025-12-16",{"date":100,"type":21},"2027-04-01",{"name":102,"class":72},"University of Haifa",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":73},"100588169","transdiagnostic-metacognitive-therapy-compared-to-disorder-specific-cognitive-behavioral-therapy-for-anxiety-disorders-100588169","NCT06937892","Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders","Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders: A Randomized Controlled Superiority Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* A principal (most interfering and\u002For severe) diagnosis of GAD, SAD or PTSD\n* If on pharmacological treatment, no change in dose during the last six weeks\n* Ability to read and speak Swedish\n\nExclusion Criteria:\n\n* A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder\n* Acute risk of suicide\n* Simultaneous psychological treatment",{"count":111,"type":21},86,[57],"Background\n\nAnxiety disorders are the most prevalent psychiatric disorders around the world.\n\nEffective treatment consists of pharmacotherapy or psychological treatment based on cognitive-behavioral therapy (CBT) and these treatment options are recommended in clinical guidelines, with CBT as the first-line treatment for anxiety disorders. However, only 50% of patients with anxiety disorders achieve remission status following CBT and 20% of patients drop out of CBT.\n\nMetacognitive therapy (MCT) represents an alternative treatment approach to CBT. The theoretical model of MCT emphasizes the role of dysfunctional metacognitions (rather than cognitions, as in CBT), particularly negative metacognitions, in the development and maintenance of anxiety disorders and other psychiatric disorders. Metacognitions refer to cognitions about cognition, for example, a belief such as \"When I start worrying, I cannot stop\". Several meta-analyses indicate that MCT may be superior to CBT for various psychiatric disorders. However, more studies with larger samples are required to draw firm conclusions about the effectiveness of MCT.\n\nAn alternative approach to disorder-specific treatment is transdiagnostic treatment; that is, the application of a single, generic protocol for several disorders. There are advantages of transdiagnostic treatments in comparison to disorder-specific treatments in terms of therapist learnability (i.e., easier to learn one protocol than several) and dissemination into routine care. Despite the MCT model being described as applicable to a range of psychiatric disorders and MCT as a potentially transdiagnostic approach, at present there is only one sufficiently large study that compared transdiagnostic MCT (tMCT) to disorder-specific CBT.\n\nPurpose and aims\n\nThe purpose of the present project is to investigate the effectiveness of tMCT compared to disorder-specific CBT in patients with anxiety disorders in psychiatric care and evaluate the cost-effectiveness. Aim 1 is to compare the short- and long-term effects of tMCT and CBT, from pre- to post-assessment and from post-assessment to 6- and 12-month follow-up assessments. Aim 2 is to examine possible mediators of change (metacognitions and cognitions). Aim 3 is to compare the cost-effectiveness of tMCT to CBT.\n\nDesign and setting\n\nThe project has a prospective, pragmatic, two-arm parallel-group randomized controlled superiority trial design and is conducted in psychiatric services in Stockholm, Sweden. Treatment is conducted in an individual format and face-to-face.\n\nRandomization and blinding\n\nEach participant is stratified individually on principal diagnosis prior to randomization and then randomly allocated with a 1:1 ratio to tMCT or CBT. A list of random numbers is generated for each diagnosis for each psychiatric unit by an individual independent of the project. Researchers, therapists, participants, and independent assessors are blinded to the allocation sequence. Assessors are also blinded to treatment condition at post-treatment assessment. Researchers are blinded to treatment allocation in the analysis phase at all assessment points.\n\nTherapist training and supervision\n\nTherapists are licensed psychologists or psychotherapists with prior training in CBT and employed in psychiatric services in Stockholm, Sweden. Only therapists who can show competence in MCT and CBT, respectively, are allowed to treat participants in the project.\n\nProcedure\n\nPatients are consecutively assessed for eligibility by project therapists. As part of routine clinical care, patients are assessed for principal and comorbid diagnoses. Patients meeting criteria for GAD, SAD, or PTSD are assessed whether they meet other inclusion but not exclusion criteria for participation in the project. Patients provide written informed consent to therapists. At pre-treatment, participants complete outcome measures. Participants are then randomly assigned to tMCT or CBT. Following the last session, and at 6-month and 12-month follow-up assessments, participants complete the same measures as at pre-treatment. In addition, at post-treatment principal and comorbid diagnoses are assessed by independent assessors.\n\nData analysis\n\nMultilevel modeling is used to estimate between-group effects on outcome measures from pre- to post-assessment (following treatment completion; primary endpoint), and from post-assessment to 6- and 12-month follow-up assessments. To be comparable across diagnoses, scores on the primary outcome of disorder-specific measures are standardized by calculating z-scores. Missing data are estimated using maximum likelihood estimation. Data from all randomized participants are used in the multilevel models, following the principle of intention-to-treat.\n\nA detailed study protocol has been submitted for publication.",[115,27,116],"Generalized Anxiety Disorder (GAD)","Posttraumatic Stress Disorder (PTSD)",[118,119,120,121],"Metacognitive therapy","Cognitive-behavioral therapy","Transdiagnostic treatment","Anxiety disorders","2026-03-23",{"date":124,"type":38},"2026-03-27",{"date":126,"type":38},"2025-08-27",{"date":128,"type":21},"2028-12",{"name":130,"class":72},"Karolinska Institutet",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":73},"100628794","intermittent-theta-burst-stimulation-of-the-prefrontal-cortex-in-social-anxiety-disorder-100628794","NCT07466277","Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Social Anxiety Disorder","Intermittent Theta-Burst Stimulation Targeting the Prefrontal Cortex for Social Anxiety Disorder: A Randomized, Parallel-Group Comparative Study","Inclusion Criteria: Eligible participants must be right-handed individuals aged 16 to 70 years who meet the diagnostic criteria for Social Anxiety Disorder (SAD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). If participants are taking concurrent psychiatric medications, their dosage must have been stable for at least 4 weeks prior to enrollment. Additionally, all individuals must voluntarily agree to participate in the study and provide written informed consent.\n\nExclusion Criteria: Individuals will be excluded if they have a history of neurological disorders or other severe somatic diseases, including but not limited to seizures, central nervous system tumors, stroke, or brain aneurysms. Participants meeting DSM-5 diagnostic criteria for other primary psychiatric disorders-such as schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, other anxiety disorders, obsessive-compulsive and related disorders, or somatic symptom and related disorders-are also ineligible. Furthermore, the study excludes those with metallic implants in the head or neck, any other clear contraindications to Transcranial Magnetic Stimulation (TMS), or a previous history of receiving TMS treatment, which is restricted to prevent potential unblinding. Finally, current use, or use within the past 4 weeks, of adequate doses of benzodiazepines for more than 2 weeks is an exclusion criterion, as it may limit the therapeutic efficacy of TMS.","16 Years","70 Years",{"count":84,"type":21},[57],"This study aims to investigate the therapeutic effects of intermittent theta burst stimulation on social anxiety disorder and to track physiological changes in the brain using electroencephalography (EEG). Eligible SAD participants, after voluntarily signing an informed consent form, will first complete basic information collection, baseline questionnaire completion, and a pre-treatment EEG data collection session lasting approximately 30 minutes (including resting-state and task-state recordings). Subsequently, participants will be randomly assigned to one of three groups (left iTBS group, right iTBS group, or sham stimulation group) to receive intensive treatment for one week (4 sessions daily for 5 consecutive days, totaling 20 sessions). Immediately following the intervention, the research team will conduct post-treatment EEG data collection and gather questionnaire assessments. Participants will also undergo follow-up visits at weeks 2, 4, 6, and 8 post-treatment to complete questionnaires and report any adverse events. All study procedures are strictly and safely conducted by trained professionals. Participation is entirely voluntary, and participants may withdraw unconditionally at any time during the study.",[27],[29,145,146,147],"Transcranial Magnetic Stimulation","Intermittent Theta-Burst Stimulation","Prefrontal Cortex","2026-03-11",{"date":150,"type":38},"2026-03-12",{"date":152,"type":38},"2025-12-09",{"date":154,"type":21},"2026-12-01",{"name":156,"class":72},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":17,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":73},"100628053","actsocially-the-dissimilarities-of-act-for-changing-internalizing-and-externalizing-symptomatology-in-adolescence-100628053","NCT07456631","ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence","ACTsocially","Inclusion Criteria:\n\nStudy I:\n\n* Main diagnosis of Oppositional Defiant Disorder (ODD)\n* Meeting diagnostic criteria for Social Anxiety Disorder (SAD)\n\nStudy II:\n\n* Main diagnosis of Social Anxiety Disorder (SAD)\n* Meeting diagnostic criteria for Oppositional Defiant Disorder (ODD)\n\nExclusion Criteria (applies to both studies):\n\n* Impaired cognitive development based on school records\n* Presence of psychotic symptoms according to the diagnostic interview\n* Diagnosis of autism spectrum disorder according to the diagnostic interview\n* Currently undergoing another psychological intervention for a psychiatric condition\n\nNote: Comorbid conditions other than the co-occurrence of ODD and SAD will not be considered exclusion criteria.","12 Years",{"count":166,"type":21},54,[57],"Social functioning, fundamental to adolescent's development and mental health, may be impaired by polarizing problematic social functioning, namely externalizing symptoms manifested by Oppositional Defiant Disorder and internalizing symptoms portrayed by Social Anxiety Disorder. Despite their high prevalence and similar associated impairments, interventions targeting these disorders are differently conceived. Alternatively, Acceptance and Commitment Therapy (ACT) proposes that those apparently dissimilar social difficulties are rooted in similar processes. Though research has shown ACTs' efficacy in changing adults' internalizing and externalizing symptoms, studies on the potential of ACT in changing those problematics in adolescence are still scarce. This project proposes to conduct three clinical trials to test the efficacy and (dis)similarities of an transdiagnostic ACT intervention for changing internalizing and externalizing symptomatology in adolescents. It will amplify the transdiagnostic and evidence-based application of ACT to adolescents presenting polarizing disorders in the social functioning spectrum.",[27,170],"Oppositional Defiant Disorder",[172,173,170,29,174,175],"Acceptance and Commitment Therapy","Adolescents","Psychological Flexibility","Psychological Inflexibility","2026-03-06",{"date":178,"type":38},"2026-03-10",{"date":180,"type":38},"2023-09-01",{"date":182,"type":21},"2027-09-30",{"name":184,"class":72},"University of Coimbra",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":73},"100610481","stepped-care-treatment-for-anxiety-resilience-100610481","NCT07228143","Stepped Care Treatment for Anxiety Resilience","Stepped Care Cognitive Behavioral Therapy for Children and Adolescents With Anxiety","STAR","Inclusion Criteria:\n\n* A primary diagnosis of OCD or an anxiety disorder including separation anxiety disorder, social phobia, generalized anxiety disorder, specific phobia, agoraphobia, panic disorder, as determine by an IE using the DIAMOND-KID diagnostic interview.\n* Score of ≥ 14 on the PARS (items 2-7) which corresponds to clinically significant anxiety.\n* The child is 7-17 years old.\n* Residence in Texas and located in the state of Texas during treatment sessions.\n\nExclusion Criteria:\n\n* -Psychosis, cognitive disability, any condition that would limit the caregiver's ability to follow instructions.\n* Parent substance use disorder within the past 3 months, which could impact their ability to implement step 1\n* Child or parent is suicidal. A delayed entry once the parent or child is stabilized (\\>6 months post suicidality) and no longer has suicidal ideation will be allowed if appropriate.\n* New pharmacological interventions or treatment changes: Initiation of an antidepressant within 12 weeks before study enrollment or 6 weeks for an antipsychotic, benzodiazepine, or attention deficit hyperactivity disorder (ADHD) medication before enrollment, or any change in established psychotropic medication (e.g., antidepressants, anxiolytics) within 6 weeks before study enrollment (4 weeks for antipsychotic, anti-anxiety, benzodiazepine, or ADHD medication changes). Medications will remain stable during treatment.","7 Years","17 Years",{"count":196,"type":21},106,[57],"Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed.\n\nThe stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child.\n\nWhile stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change.\n\nThis research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.",[115,27,200,201,202,203],"Separation Anxiety Disorder","Specific Phobia","Obsessive Compulsive Disorder (OCD)","Panic Disorder (With or Without Agoraphobia)",[205,206,173,207,208,209],"Anxiety","Child","Obsessive compulsive disorder","stepped care","psychotherapy","2026-02-27",{"date":212,"type":38},"2026-03-02",{"date":214,"type":38},"2026-01-05",{"date":216,"type":21},"2028-04-30",{"name":218,"class":72},"Andrew Wiese",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":5},"100617835","phase-2-a-study-of-ntx-1472-in-social-anxiety-disorder-100617835","NCT07323784","A Study of NTX-1472 in Social Anxiety Disorder","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder","SOAR","Key Inclusion Criteria\n\n* Has provided written informed consent for the study and is willing to comply with all requirements of the protocol\n* English speaker\n* Male or female, ≥18 and ≤65 years of age\n* Current diagnosis of generalized Social Anxiety Disorder (SAD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) and confirmed by the Structured Clinical Interview for DSM-5 (SCID-5-CT).\n* Clinician-administered Liebowitz Social Anxiety Score (LSAS) total score ≥70 at Screening\n* Clinician-rated Hamilton Depression Rating Scale (HDRS 17) (17 items) total score \\\u003C16 at Screening\n* If participant is of childbearing potential, must commit to practicing effective methods of birth control during the study and at least 14 days after the last dose.\n\nKey Exclusion Criteria\n\n* Current diagnosis of performance-only SAD as defined by the DSM-5 and confirmed by the SCID-5-CT.\n* Current diagnosis of any of the following psychiatric condition(s) as defined by the DSM-5 (participants with current generalized anxiety disorder may be included): Attention-deficit\u002Fhyperactivity disorder, Autism spectrum disorder, Major depressive disorder, Personality disorder, Post-traumatic stress disorder.\n* Past or current diagnosis of any of the following psychiatric condition(s), as defined by the DSM-5: Bipolar disorder, Feeding and eating disorder (in adulthood), Obsessive-compulsive disorder, Schizophrenia spectrum or other psychotic disorder, Substance use disorder (within 12 months of Screening).\n* Receiving daily psychotropics within 4 weeks of Screening\n* Is at risk for suicidal ideation as per C-SSRS\n* Has moderate or severe hepatic impairment\n* Has severe renal impairment\n* Women who are pregnant or women who are currently breastfeeding unless they are willing to stop breastfeeding for the duration of the study.",{"count":84,"type":21},[229],"PHASE2","The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are:\n\n* Is NTX-1472 safe and well tolerated in adults with SAD?\n* How effectively does NTX-1472 treat adults with SAD?\n\nResearchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug).\n\nParticipants will:\n\n* Take NTX-1472 or matching placebo every day for 8 weeks\n* Visit the clinic 6 times over the course of 14 weeks for checkups and tests",[27],"2026-01-16",{"date":234,"type":38},"2026-01-21",{"date":152,"type":38},{"date":237,"type":21},"2027-01",{"name":239,"class":45},"Newleos Therapeutics, Inc.",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":247,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100583473","virtual-reality-based-cognitive-behavioral-therapy-for-social-anxiety-among-youths-in-hong-kong-100583473","NCT06876779","Virtual Reality Based Cognitive Behavioral Therapy for Social Anxiety Among Youths in Hong Kong","Virtual Reality Based Cognitive Behavioral Therapy for Social Anxiety-Driven Depression Among Youths: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. youths aged between 15 and 24 years old; and\n2. scoring above 24 on the Social Phobia Inventory.\n\nExclusion Criteria:\n\n1. unable to attempt a baseline assessment (e.g., due to being unpermitted to leave a psychiatric ward);\n2. photosensitive epilepsy;\n3. significant visual, auditory, or balance impairment;\n4. currently receiving another intensive psychological intervention; and\n5. currently holding active suicidal plans",true,"15 Years","24 Years",{"count":55,"type":21},[57],"This randomized controlled trial evaluates the effectiveness of a VR-based CBT intervention for social anxiety-driven depression among Hong Kong youth (ages 15-24). Given the limitations of traditional CBT in addressing deep-seated fears, this study explores a more engaging and scalable alternative. Ninety participants with depressive symptoms and social difficulties will undergo six 60-minute VR sessions based on Clark and Wells' cognitive model of social phobia, with assessments at baseline, post-treatment, and three-month follow-up using the Social Phobia Inventory and PHQ-9. The study investigates whether VR intervention reduces social anxiety-driven depression and assesses its cost-effectiveness. Expected outcomes include symptom reduction, sustained benefits at follow-up, and evidence for VR as an innovative, scalable mental health intervention, informing clinical practice, research, and policy in Hong Kong and beyond.",[27,30],"NOT_YET_RECRUITING","2025-09-08",{"date":257,"type":38},"2025-09-15",{"date":259,"type":21},"2025-11-01",{"date":261,"type":21},"2026-12-30",{"name":263,"class":72},"Hong Kong Shue Yan University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":73},"100590766","metacognitive-therapy-vs-unified-protocol-for-patients-with-comorbid-anxiety-disorders-100590766","NCT06971692","Metacognitive Therapy vs Unified Protocol for Patients With Comorbid Anxiety Disorders","Transdiagnostic Therapy With Metacognitive Therapy Versus Unified Protocol for Patients With Comorbid Anxiety Disorders: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or above\n* Ability to read and speak Swedish\n* A principal diagnosis of post-traumatic stress disorder, generalized anxiety disorder, social anxiety disorder, or panic disorder\n* At least one additional comorbid diagnosis (one of the above diagnoses, or obsessive-compulsive disorder, or major depressive disorder)\n* Patients on psychotropic medication must have been on a stable dose (excluding as-needed medication) for at least six weeks prior to treatment initiation\n\nExclusion Criteria:\n\n* Current diagnosis of psychosis, bipolar disorder or moderate to severe substance use disorder\n* Medium to high suicide risk\n* Psychiatric, somatic or social problems that require primary intervention other than the treatments offered in the study\n* Concurrent psychological treatment",{"count":272,"type":21},114,[57],"The primary goal of this randomized controlled trial is to compare the effectiveness of two transdiagnostic psychological treatments, Metacognitive Therapy (MCT) and the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), for patients with complex anxiety.",[116,115,27,203],"2025-05-06",{"date":278,"type":38},"2025-05-14",{"date":280,"type":21},"2025-08",{"date":128,"type":21},{"name":130,"class":72},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":291,"maxAge":17,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":308},"100585343","the-covideo-study---a-trial-of-cognitive-therapy-for-social-anxiety-disorder-in-youth-comparing-screen-to-office-delivery-100585343","NCT06901128","The Covideo Study - a Trial of Cognitive Therapy for Social Anxiety Disorder in Youth, Comparing Screen to Office Delivery","The Covideo Study - a Randomized Controlled Trial of Cognitive Therapy for Social Anxiety Disorder in Youth, Comparing Screen to Office Delivery","Covideo","Inclusion Criteria:\n\n* Social anxiety disorder primary\n* Age 14 to 18 years.\n* Norwegian fluency\n\nExclusion Criteria:\n\n* Severe Depression\n* Acute suicidality\n* Substance abuse\n* Psychosis\n* Intellectual Disability\n* More than 20% absence from school in previous three months","14 Years",{"count":293,"type":21},200,[57],"The main goal of this clinical trial is to examine screen delivery as an alternative for offering cognitive therapy to youth with social anxiety. It will examine its effectiveness compared to office delivery, but also its acceptability and sustainability, and identify factors important for the outcome of this approach.\n\nThe main questions it aims to answer are:\n\nDoes screen delivery show comparable effectiveness to office delivery? Is screen delivery well accepted by youth and therapists? Does screen delivery show economic and climate sustainability? Do credibility and therapeutic alliance predict therapy outcome?\n\nIn the study researchers will compare screen delivery to office delivery of cognitive therapy for social anxiety disorders in 200 youth aged 14-18 years.\n\nAfter an initial screening in schools, eligible youth are assessed with a diagnostic interview. Those meeting inclusion criteria will be offered either screen or office therapy. This is decided by random selection (a draw).\n\nParticipants will:\n\nComplete an initial short screening questionnaire. Respond to a diagnostic interview online. Meet their therapist first time in person. Attend 14 weekly 90-minutes therapy session. Complete weekly questionnaires during the therapy. Answer interview and questionnaires after the therapy, and also 6 months, 2 years and 4 years later. Parents are also interviewed and informed of the study.",[27],[298],"RCT video screen delivery cognitive therapy youth","2025-03-26",{"date":301,"type":38},"2025-03-28",{"date":303,"type":21},"2025-04-01",{"date":305,"type":21},"2035-12-31",{"name":307,"class":72},"Sykehuset Innlandet HF",5]